Pathogenic Protein Reduction Program
Neurodegenerative Diseases (e.g., Alzheimer's)
PreclinicalActive
Key Facts
Indication
Neurodegenerative Diseases (e.g., Alzheimer's)
Phase
Preclinical
Status
Active
Company
About Talisman Therapeutics
Talisman Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Cambridge, UK. It operates a dual business model, focusing internally on discovering novel therapeutics for neurodegenerative diseases while also providing access to its human iPSC-based neuroscience platform to external partners. The company's core strategy is to overcome the limitations of traditional neurological drug discovery by using human genetics-informed, stem cell-derived models to identify and validate new targets and drug candidates.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases (e.g., Alzheimer's) Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC-based Therapy | Kyttaro | Pre-clinical |